Precision Molecular Pathology of Aggressive B-Cell Lymphomas
Precision Molecular Pathology of Aggressive B-Cell Lymphomas
Buch
- Herausgeber: Sanam Loghavi, Genevieve M. Crane
- Springer International Publishing, 02/2024
- Einband: Gebunden, HC runder Rücken kaschiert
- Sprache: Englisch
- ISBN-13: 9783031468414
- Bestellnummer: 11765825
- Umfang: 460 Seiten
- Auflage: 2023
- Gewicht: 929 g
- Maße: 241 x 160 mm
- Stärke: 29 mm
- Erscheinungstermin: 15.2.2024
- Serie: Molecular Pathology Library
Achtung: Artikel ist nicht in deutscher Sprache!
Klappentext
Written by experts in the field, Precision Molecular Pathology of Aggressive B-Cell Lymphomas contains the most recent revisions from the 5th Edition WHO and 2022 International Consensus Classification diagnostic categories and serves as an important resource for trainees, pathologists, haematologist / oncologists, other clinicians involved in lymphoma care and lymphoma researchers. It provides a comprehensive yet concise synthesis of emerging molecular advances that inform patient care and improve understanding of disease mechanisms. In addition, it provides the necessary background to how molecular techniques are performed to enable the reader to better interpret and critically evaluate relevant and emerging data.As part of the Molecular Pathology Library series, this book focuses specifically on aggressive B-cell lymphomas given the increasing relevance of molecular data for diagnosis and treatment of these disorders. This evidence-based text contains 25 chapters and is divided into 5 parts. Part 1 provides a brief history and background of aggressive B-cell lymphomas. Landmark events in their classification and treatment are given in order to place the substantial advances in the field in context. Part 2 reviews molecular pathology methods, including the increasing use of next generation sequencing techniques in clinical practice. Parts 3 and 4 focus on individual subtypes of aggressive B-cell lymphoma, including a summary of the diagnostic criteria and key pathologic and clinical features for each entity. Finally, Part 5 focuses on emerging molecular technologies that may significantly impact clinical practice.